BMY - Bristol-Myers Squibb Sales Growth YoY (Last Twelve Months)

Pressure on operating leverage is increasing due to the loss of patent protection for legacy drugs, yet Bristol-Myers Squibb (BMY) maintains physician confidence through its authority in cardiology and oncology. A broad portfolio of proven medications ensures high margins, as evidenced by the current 12-month trailing revenue dynamics, where the current value stands at 4.20, confirming the revenue resilience of this behemoth.
Bristol-Myers Squibb - analytical breakdowns and key metrics (BMY)

Bristol-Myers Squibb (BMY) revenues depend on the performance of blockbuster drugs and the success of M&A deals aimed at mitigating patent risks. By analyzing year-over-year revenue changes over the trailing twelve months (TTM), an investor can observe a smoothed business expansion percentage stripped of market noise, where stable growth confirms the efficacy of new drugs, while sharp spikes may signal an overvaluation of the asset.